| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| JAZZJazz Pharmaceuticals plc | 10.4B | 171.16 | 19.79 | 6.12% | -8.86% | -9.31% | 12.96% | 1.51 |
| ACADACADIA Pharmaceuticals Inc. | 4.49B | 26.53 | 19.51 | 31.85% | 24.94% | 28.47% | 3.5% | 0.07 |
| CPRXCatalyst Pharmaceuticals, Inc. | 2.82B | 22.96 | 17.53 | 23.49% | 37.63% | 23.64% | 8.48% | 0.00 |
| HRMYHarmony Biosciences Holdings, Inc. | 2.1B | 36.41 | 14.51 | 22.8% | 22.48% | 22.23% | 10.43% | 0.28 |
| ALKSAlkermes plc | 5.15B | 31.22 | 14.39 | -6.36% | 22.27% | 19.55% | 7.87% | 0.05 |
| PRTCPureTech Health plc | 463.31M | 19.17 | 9.59 | 44.98% | -495.91% | -8.53% | 0.05 | |
| LBRXLB Pharmaceuticals Inc Common Stock | 540.89M | 21.38 | -1.20 | |||||
| NMRANeumora Therapeutics, Inc. Common Stock | 361.97M | 2.13 | -1.39 | -178.79% | 0.01 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 1.25M | 0 | 0 | 0 | 1.09M | 1.11M | -227K | 1.06M | 486K |
| Revenue Growth % | - | - | -1% | - | - | - | 0.02% | -1.2% | 5.69% | -0.54% |
| Cost of Goods Sold | 53.5K | 0 | 80.7K | 91.2K | 103.1K | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | 1.25M | 0 | 0 | -103.1K | 1.09M | 1.11M | -227K | 1.06M | 486K |
| Gross Margin % | - | 1% | - | - | - | 1% | 1% | 1% | 1% | 1% |
| Gross Profit Growth % | - | - | -1% | - | - | 11.57% | 0.02% | -1.2% | 5.69% | -0.54% |
| Operating Expenses | 17.85M | 11.5M | 14.2M | 24.53M | 19.87M | 19.02M | 48.89M | 59.04M | 34.09M | 56.46M |
| OpEx % of Revenue | - | 9.2% | - | - | - | 17.46% | 44.09% | -260.09% | 32.03% | 116.17% |
| Selling, General & Admin | 13.92M | 5.87M | 6.44M | 7.43M | 6.55M | 7.1M | 13.25M | 14.66M | 14.06M | 17.08M |
| SG&A % of Revenue | - | 4.69% | - | - | - | 6.51% | 11.95% | -64.6% | 13.22% | 35.15% |
| Research & Development | 3.93M | 5.2M | 7.76M | 17.1M | 13.33M | 11.93M | 35.41M | 44.38M | 20.02M | 39.38M |
| R&D % of Revenue | - | 4.16% | - | - | - | 10.95% | 31.93% | -195.49% | 18.82% | 81.02% |
| Other Operating Expenses | -2.3K | 426.8K | 0 | -48.7K | 0 | -400 | 232K | 0 | 0 | 0 |
| Operating Income | -17.85M | -10.25M | -14.2M | -24.56M | -19.97M | -17.93M | -47.78M | -59.27M | -33.02M | -55.97M |
| Operating Margin % | - | -8.2% | - | - | - | -16.46% | -43.09% | 261.09% | -31.03% | -115.17% |
| Operating Income Growth % | -1.63% | 0.43% | -0.39% | -0.73% | 0.19% | 0.1% | -1.66% | -0.24% | 0.44% | -0.7% |
| EBITDA | -17.8M | -10.19M | -14.12M | -24.47M | -19.87M | -17.46M | -47.07M | -58.74M | -32.45M | -55.34M |
| EBITDA Margin % | - | -8.15% | - | - | - | -16.02% | -42.45% | 258.75% | -30.5% | -113.86% |
| EBITDA Growth % | -1.65% | 0.43% | -0.39% | -0.73% | 0.19% | 0.12% | -1.7% | -0.25% | 0.45% | -0.71% |
| D&A (Non-Cash Add-back) | 53.5K | 54.9K | 80.7K | 91.2K | 103.1K | 477.6K | 711.1K | 532K | 568K | 635K |
| EBIT | -17.85M | -9.82M | -14.33M | -24.56M | -20.76M | -17.92M | -47.76M | -59.27M | -33.02M | -55.97M |
| Net Interest Income | 0 | -4.6K | 0 | -8K | 30K | 2K | 20K | 26K | 3.35M | 4.56M |
| Interest Income | 0 | 0 | 0 | 0 | 45K | 15K | 20K | 49K | 3.35M | 4.56M |
| Interest Expense | 777K | 5K | 8.9K | 8K | 15K | 13K | 0 | 23K | 0 | 0 |
| Other Income/Expense | -29.37M | -4.6K | -143.9K | -30.7K | -796.9K | 2.2K | 19.9K | 26K | 3.66M | 4.56M |
| Pretax Income | -47.22M | -10.25M | -14.34M | -24.59M | -20.77M | -17.93M | -47.76M | -59.24M | -29.36M | -51.41M |
| Pretax Margin % | - | -8.2% | - | - | - | -16.46% | -43.07% | 260.98% | -27.59% | -105.78% |
| Income Tax | 2.3K | 2.4K | 2.4K | 2.6K | 2.6K | 2.6K | 3.4K | 6K | 4K | 7K |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -47.22M | -10.26M | -14.35M | -24.59M | -20.77M | -17.93M | -47.76M | -59.25M | -29.36M | -51.42M |
| Net Margin % | - | -8.2% | - | - | - | -16.46% | -43.07% | 261% | -27.6% | -105.8% |
| Net Income Growth % | -2.4% | 0.78% | -0.4% | -0.71% | 0.16% | 0.14% | -1.66% | -0.24% | 0.5% | -0.75% |
| Net Income (Continuing) | -47.22M | -10.26M | -14.35M | -24.59M | -20.77M | -17.93M | -47.76M | -59.25M | -29.36M | -51.42M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -801.27 | -40.85 | -30.98 | -25.83 | -14.21 | -14.74 | -7.38 | -8.51 | -1.52 | -1.67 |
| EPS Growth % | -1.54% | 0.95% | 0.24% | 0.17% | 0.45% | -0.04% | 0.5% | -0.15% | 0.82% | -0.1% |
| EPS (Basic) | -801.28 | -40.85 | -30.98 | -25.83 | -14.21 | -14.74 | -7.38 | -8.51 | -1.52 | -1.67 |
| Diluted Shares Outstanding | 58.93K | 251.05K | 463K | 952.08K | 1.46M | 2.87M | 6.6M | 6.96M | 19.35M | 30.71M |
| Basic Shares Outstanding | 58.93K | 251.05K | 463K | 952.08K | 1.46M | 2.87M | 6.6M | 6.96M | 19.35M | 30.71M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 855.3K | 3.38M | 11.02M | 13.65M | 1.58M | 104.12M | 71M | 17.51M | 120.67M | 82.08M |
| Cash & Short-Term Investments | 428.5K | 2.92M | 10.38M | 13.1M | 1.36M | 103.11M | 68.14M | 16.64M | 119.17M | 80.48M |
| Cash Only | 428.5K | 2.92M | 10.38M | 13.1M | 1.36M | 103.11M | 68.14M | 16.64M | 119.17M | 67.13M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13.35M |
| Accounts Receivable | 0 | 0 | 0 | 300K | 0 | 40.6K | 2.75M | 802.7K | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | 13.6 | 903.79 | -1.29K | - | - |
| Inventory | 0 | 0 | 0 | 230.4K | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | 922.11 | - | - | - | - | - | - |
| Other Current Assets | 399.8K | 0 | 556.5K | 154.6K | 117.9K | 159.9K | -2.22M | 66.3K | 0 | 1.59M |
| Total Non-Current Assets | 134.5K | 334.3K | 255.2K | 360.5K | 4.19M | 4.16M | 3.65M | 3.58M | 2.98M | 2.27M |
| Property, Plant & Equipment | 87.6K | 286.5K | 207.4K | 312.7K | 3.79M | 3.59M | 3.08M | 2.77M | 2.25M | 1.81M |
| Fixed Asset Turnover | - | 4.36x | - | - | - | 0.30x | 0.36x | -0.08x | 0.47x | 0.27x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 46.9K | 47.8K | 47.8K | 47.8K | 402.9K | 576.8K | 569.1K | 815K | 726K | 454K |
| Total Assets | 989.8K | 3.71M | 11.28M | 14.01M | 5.77M | 108.28M | 74.64M | 21.09M | 123.65M | 84.34M |
| Asset Turnover | - | 0.34x | - | - | - | 0.01x | 0.01x | -0.01x | 0.01x | 0.01x |
| Asset Growth % | 2.67% | 2.75% | 2.04% | 0.24% | -0.59% | 17.76% | -0.31% | -0.72% | 4.86% | -0.32% |
| Total Current Liabilities | 1.79M | 1.37M | 1.46M | 2.8M | 2.77M | 4.19M | 5.77M | 4.57M | 5.12M | 12.61M |
| Accounts Payable | 936K | 867.3K | 1.2M | 1.05M | 1.84M | 838.3K | 2.76M | 2.47M | 1.55M | 653K |
| Days Payables Outstanding | 6.39K | - | 5.41K | 4.22K | 6.5K | - | - | - | - | - |
| Short-Term Debt | 43.6K | 54.8K | 53.9K | 57.3K | 56.5K | 0 | 0 | 105K | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 1000K | 1000K | 714K | 0 | 1000K |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 66.2K | 337K | 791K | 3.36M |
| Current Ratio | 0.48x | 2.47x | 7.56x | 4.87x | 0.57x | 24.85x | 12.32x | 3.83x | 23.55x | 6.51x |
| Quick Ratio | 0.48x | 2.47x | 7.56x | 4.79x | 0.57x | 24.85x | 12.32x | 3.83x | 23.55x | 6.51x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 2.17M | 1.73M | 2.9M | 4.14M | 8.73M | 12.11M | 4.16M | 4.43M | 4.24M | 1.34M |
| Long-Term Debt | 27.2K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 11.9K | 9.3K | 6.3K | 3.72M | 3.35M | 2.61M | 2.12M | 1.57M | 948K |
| Deferred Tax Liabilities | -55.5K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 2.15M | 1.72M | 2.89M | 4.13M | 5.01M | 6.27M | 0 | 0 | 2.67M | 0 |
| Total Liabilities | 3.97M | 3.1M | 4.36M | 6.94M | 11.5M | 16.3M | 9.93M | 9.01M | 9.37M | 13.95M |
| Total Debt | 71.9K | 69.1K | 65.8K | 66.6K | 4.09M | 3.72M | 3.04M | 2.71M | 2.12M | 1.51M |
| Net Debt | -356.6K | -2.85M | -10.31M | -13.03M | 2.74M | -99.39M | -65.1M | -13.93M | -117.05M | -65.62M |
| Debt / Equity | - | 0.11x | 0.01x | 0.01x | - | 0.04x | 0.05x | 0.22x | 0.02x | 0.02x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -22.97x | -2049.70x | -1595.46x | -3069.54x | -1331.63x | -1379.52x | - | -2576.87x | - | - |
| Total Equity | -2.98M | 615.8K | 6.92M | 7.08M | -5.73M | 91.98M | 64.72M | 12.08M | 114.29M | 70.39M |
| Equity Growth % | 0.86% | 1.21% | 10.23% | 0.02% | -1.81% | 17.05% | -0.3% | -0.81% | 8.46% | -0.38% |
| Book Value per Share | -50.52 | 2.45 | 14.94 | 7.43 | -3.92 | 32.04 | 9.81 | 1.74 | 5.90 | 2.29 |
| Total Shareholders' Equity | -2.98M | 615.8K | 6.92M | 7.08M | -5.73M | 91.98M | 64.72M | 12.08M | 114.29M | 70.39M |
| Common Stock | 2.6K | 9K | 23.1K | 42.8K | 49.3K | 180.8K | 6.9K | 7K | 27K | 29K |
| Retained Earnings | -131.74M | -142M | -156.54M | -181.13M | -201.91M | -219.84M | -267.6M | -326.85M | -356.21M | -407.63M |
| Treasury Stock | -3.97M | -3.97M | -3.97M | -3.97M | -3.97M | -3.97M | -3.97M | -3.97M | -3.97M | -3.97M |
| Accumulated OCI | -6.5K | -4K | -4K | -4K | 0 | 0 | 0 | 0 | 0 | 5K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -4.81M | -7.26M | -9.06M | -14.53M | -15.76M | -12.07M | -45.26M | -49.72M | -25.81M | -42.1M |
| Operating CF Margin % | - | -5.81% | - | - | - | -11.08% | -40.81% | 219.01% | -24.26% | -86.62% |
| Operating CF Growth % | -0.74% | -0.51% | -0.25% | -0.6% | -0.08% | 0.23% | -2.75% | -0.1% | 0.48% | -0.63% |
| Net Income | -47.22M | -10.26M | -14.35M | -24.59M | -20.77M | -17.93M | -47.76M | -59.25M | -29.36M | -51.42M |
| Depreciation & Amortization | 53.5K | 54.9K | 80.7K | 91.2K | 103.1K | 477.6K | 711.1K | 532K | 568K | 635K |
| Stock-Based Compensation | 4.04M | 851.3K | 2.34M | 3.44M | 3.82M | 2.31M | 3.48M | 3.34M | 2.18M | 4.32M |
| Deferred Taxes | 36.06M | 751.5K | 439K | 145.5K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 2.78M | 2.02M | 1.75M | 4.66M | 932.8K | 0 | 232K | 3.64M | 6K | -389K |
| Working Capital Changes | -521.5K | -679.4K | 672.9K | 1.72M | 160.3K | 3.08M | -1.92M | 2.03M | 793K | 4.76M |
| Change in Receivables | 0 | 0 | 0 | -300K | 300K | -40.6K | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | -20.77M | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -547.2M | -451.7M | 135M | 22.7M | 0 | 0 | 1.69B | 0 | 522K | 5.68M |
| Cash from Investing | -26.3K | -239.1K | -1.6K | -174K | 0 | -275.4K | -200.4K | -740K | -61K | -13.15M |
| Capital Expenditures | -26.3K | -239.1K | -1.6K | -174K | 0 | -275.4K | -200.4K | -212K | -61K | -191K |
| CapEx % of Revenue | - | 0.19% | - | - | - | 0.25% | 0.18% | -0.93% | 0.06% | 0.39% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -239.1M | -1.6M | -174M | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 5.19M | 9.99M | 16.52M | 17.42M | 4.01M | 114.1M | 10.48M | -1.04M | 128.4M | 3.21M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | -1.26B | -1.03B | -1.14B | 0 | 0 | -945.1M | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 5.31M | 1.27B | 1.05B | 1.16B | 710K | 5.01M | 951.15M | 63K | 8K | 201K |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -4.83M | -7.5M | -9.06M | -14.7M | -15.76M | -12.35M | -45.46M | -49.93M | -25.87M | -42.29M |
| FCF Margin % | - | -6% | - | - | - | -11.33% | -40.99% | 219.95% | -24.32% | -87.01% |
| FCF Growth % | -0.75% | -0.55% | -0.21% | -0.62% | -0.07% | 0.22% | -2.68% | -0.1% | 0.48% | -0.63% |
| FCF per Share | -82.04 | -29.88 | -19.57 | -15.44 | -10.78 | -4.30 | -6.89 | -7.17 | -1.34 | -1.38 |
| FCF Conversion (FCF/Net Income) | 0.10x | 0.71x | 0.63x | 0.59x | 0.76x | 0.67x | 0.95x | 0.84x | 0.88x | 0.82x |
| Interest Paid | 12.7K | 16.6K | 8.9K | 8K | 14.8K | 13.3K | 300 | 0 | 0 | 0 |
| Taxes Paid | 2.4K | 2.4K | 2.4K | 2.6K | 2.6K | 2.6K | 3.4K | 0 | 0 | 0 |
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -1665.39% | -380.91% | -351.49% | -3087.23% | -41.59% | -60.96% | -154.3% | -46.47% | -55.68% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | - | - | - | - | -4181.25% |
| Gross Margin | - | 100% | - | - | - | 100% | 100% | 100% | 100% | 100% |
| Net Margin | - | -820.44% | - | - | - | -1646.09% | -4307.19% | 26100.44% | -2759.59% | -10579.84% |
| Debt / Equity | - | 0.11x | 0.01x | 0.01x | - | 0.04x | 0.05x | 0.22x | 0.02x | 0.02x |
| Interest Coverage | -22.97x | -2049.70x | -1595.46x | -3069.54x | -1331.63x | -1379.52x | - | -2576.87x | - | - |
| FCF Conversion | 0.10x | 0.71x | 0.63x | 0.59x | 0.76x | 0.67x | 0.95x | 0.84x | 0.88x | 0.82x |
| Revenue Growth | - | - | -100% | - | - | - | 1.78% | -120.47% | 568.72% | -54.32% |
| 2022 | |
|---|---|
| License | 1.11M |
| License Growth | - |
VistaGen Therapeutics, Inc. (VTGN) reported $0.7M in revenue for fiscal year 2025. This represents a 46% decrease from $1.3M in 2012.
VistaGen Therapeutics, Inc. (VTGN) saw revenue decline by 54.3% over the past year.
VistaGen Therapeutics, Inc. (VTGN) reported a net loss of $62.2M for fiscal year 2025.
VistaGen Therapeutics, Inc. (VTGN) has a return on equity (ROE) of -55.7%. Negative ROE indicates the company is unprofitable.
VistaGen Therapeutics, Inc. (VTGN) had negative free cash flow of $53.1M in fiscal year 2025, likely due to heavy capital investments.